Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population

详细信息    查看全文

• 作者：Yingwen Liu ; Yanghui Bi ; Jia Lin ; Lei Cao ; Bing He ; Zhi Zhang…
• 关键词：CFI ; Tag SNPs ; NSCLC ; Genetic variants ; Single nucleotide polymorphism
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：36
• 期：3
• 页码：1955-1962
• 全文大小：454 KB
• 参考文献：1. Ferlay, J, Shin, HR, Bray, F, Forman, D, Mathers, C, Parkin, DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: pp. 2893-917 CrossRef
  2. Jemal, A, Murray, T, Samuels, A, Ghafoor, A, Ward, E, Thun, MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53: pp. 5-26 CrossRef
  3. Parkin, DM, Bray, F, Ferlay, J, Pisani, P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: pp. 74-108 CrossRef
  4. Siegel, R, Naishadham, D, Jemal, A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: pp. 10-29 CrossRef
  5. Engels, EA, Wu, X, Gu, J, Dong, Q, Liu, J, Spitz, MR (2007) Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 67: pp. 6520-7 CrossRef
  6. Young, RP, Hopkins, RJ (2013) Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer 119: pp. 1761 CrossRef
  7. Rutkowski, MJ, Sughrue, ME, Kane, AJ, Mills, SA, Parsa, AT (2010) Cancer and the complement cascade. Mol Cancer Res 8: pp. 1453-65 CrossRef
  8. Ostrand-Rosenberg, S (2008) Cancer and complement. Nat Biotechnol 26: pp. 1348-9 CrossRef
  9. Ollert, MW, David, K, Bredehorst, R, Vogel, CW (1995) Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J Immunol 155: pp. 4955-62
  10. Pangburn, MK, Pangburn, KL, Koistinen, V, Meri, S, Sharma, AK (2000) Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J Immunol 164: pp. 4742-51 CrossRef
  11. Lachmann, PJ, Muller-Eberhard, HJ (1968) The demonstration in human serum of “conglutinogen-activating factor-and its effect on the third component of complement. J Immunol 100: pp. 691-8
  12. Zhou, W (2012) The new face of anaphylatoxins in immune regulation. Immunobiology 217: pp. 225-34 CrossRef
  13. Ricklin, D, Hajishengallis, G, Yang, K, Lambris, JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: pp. 785-97 CrossRef
  14. Pio, R, Corrales, L, Lambris, JD (2014) The role of complement in tumor growth. Adv Exp Med Biol 772: pp. 229-62 CrossRef
  15. Yu, X, Rao, J, Lin, J, Zhang, Z, Cao, L, Zhang, X (2014) Tag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancer. Mol Cancer 13: pp. 56 CrossRef
  16. Travis, WD, Colby, TV, Corri, B, Shimosato, Y, Brambilla, E (1999) Histological typing of lung and pleural tumours. Springer, Berlin CrossRef
  17. Barrett, JC, Fry, B, Maller, J, Daly, MJ (2005) Haploview: analysis and visualization of ld and haplotype maps. Bioinformatics 21: pp. 263-5 CrossRef
  18. Ricklin, D, Lambris, JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25: pp. 1265-75 CrossRef
  19. Nozaki, M, Raisler, BJ, Sakurai, E, Sarma, JV, Barnum, SR, Lambris, JD (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 103:
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Complement factor I (CFI) plays an important role in the development of non-small cell lung cancer (NSCLC). This study aims to examine the association of CFI genetic variants with the risk of developing NSCLC in Chinese population. A hospital-based case-control study was conducted in 470 patients with NSCLC and 470 controls in Chinese population. Totally, 13 tag single nucleotide polymorphisms (tag SNPs) of CFI were selected by Haploview software using the HapMap database. Genotyping was performed using iPLEX Gold Genotyping Assay and Sequenom MassARRAY. The odds ratios (ORs) and 95?% confidence interval (95?% CI) were calculated by logistic regression model. Our results showed that individuals with rs6822976 GG genotype had a significant decreased risk of NSCLC (OR--.64; 95?% CI--.42-.98) when compared with rs6822976 AA genotype carriers. We also found that rs7671905 TT genotype exhibited a significant decreased risk of NSCLC compared with CC genotype with OR (95?% CI) of 0.55 (0.33-.91). There was no significant association between other selected SNPs and the risk of NSCLC. When stratified by smoking status, the decreased risk of NSCLC was observed to be associated with the genotype with at least one rs6822976 G allele among non-smokers (OR--.66; 95?% CI--.47-.93), but not among smokers (OR--.01; 95?% CI--.67-.53). For CFI rs7671905 polymorphism, the individuals with at least one T allele have a decreased risk of NSCLC with OR (95?% CI) of 0.71 (0.51-.99), but not among smokers (OR--.93; 95?% CI--.61-.41). When stratified by age, we found that rs7671905 TT genotype has contributed to the decreased risk of NSCLC among older subjects with OR (95?% CI) of 0.46 (0.23-.95), but not among younger subjects with OR (95?% CI) of 0.64 (0.31-.34) (P interaction--.03). After stratifying by sex, our study showed that rs7671905 TT genotype was related to the risk of NSCLC among males (OR--.53; 95?% CI--.29-.98), but not among females (OR--.62; 95?% CI--.25-.57) (P interaction--.03). CFI genetic variants played an important role in the development of NSCLC in Chinese population.